A Randomized, Double-blind, Placebo-controlled, Multi-centre, Sequential Design, Phase IIa Study to Evaluate Safety and Tolerability of Epicardial Injections of AZD8601 During Coronary Artery Bypass Grafting Surgery
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2018
At a glance
- Drugs AZD 8601 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors AstraZeneca
- 26 Feb 2018 Planned End Date changed from 30 Apr 2019 to 14 Jun 2019.
- 26 Feb 2018 Planned primary completion date changed from 30 Apr 2019 to 14 Jun 2019.
- 26 Feb 2018 Status changed from not yet recruiting to recruiting.